Replies to post #5587 on Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[EM]

Agree. I honestly don't see dilution in the very near term and at this price per share.

Per last presentation, they assured investors they would have funded TyrNovo with KIT-302's license agreements.

This first SK deal didn't give them upfront. I think EU and US deals will be a game changer for them in term of cash and confidence.

I have now no doubt of Dexcel's interest in KIT-302. Will they partner it in EU? For sure it will be the best EU deal for them. Dexcel ( http://www.dexcel.com/dexcel-in-numbers/ ) is one of the largest Isreali's pharmaceuticals company. Don't forget they have the right for first negotiation for KIT-302. And Who will partner it in US? Upfront payments have to be huge in order to avoid dilution in the near term. As of December 31 2016, they have approx $15mm in cash with approx $6mm in annualized cash burn.

Still no premium to the pipeline. Market wants to see KIT-302 NDA filing\Acceptance.